Ranitidine

Ranitidine

[injection $1.75; tablets 4 cents]

ADMINISTRATION ROUTES:

  • PO, IV

ALTERNATIVE NAMES:

  • Apo-Ranitidine, Zantac, Peptisoothe

ICU INDICATIONS:

  1. Ulcerprophylaxis

PRESENTATION AND ADMINISTRATION:

  • IV:
    Dilute 50mg dose to 20ml with compatible IV fluid and administer into side arm over at least 2 minutes.
    Compatible with the following IV fluids: 0.9% sodium chloride, 5% and 10% dextrose, Glucose and Sodium Chloride, Hartmann’s
  • Store at room temperature
  • PO Tablets:
    Apo-Ranitidine 150mg tablets (white), Arrow Ranitidine 150mg tablets (white), Zantac relief tablets (150mg)
  • Oral solution:
    Peptisoothe 150mg/10ml, Zantac Syrup 150mg/10ml

DOSAGE:

  • PO:
    150mg 8-12 hourly or 300mg at night
  • IV:
    50mg 8 hourly

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY:

  • Dose in renal impairment [GFR (ml/min)]:
    <10: 50-100% of normal dose
    10-20: dose as in normal renal function
    >20-50: dose as in normal renal function
  • Dose in renal replacement therapy:
    CAPD: 50-100% of normal dose
    HD: 50-100% of normal dose
    CVVHDF: dose as in normal renal function

DOSAGE IN PAEDIATRICS:

  • IV:
    1mg/kg 8 hourly
  • PO:
    2-4mg/kg 8-12 hourly

CLINICAL PHARMACOLOGY:

  • Ranitidine is a selective, competitive antagonist of histamine at H2-receptor sites

CONTRAINDICATIONS:

  1. hypersensitivity to ranitidine

WARNINGS

  • Nil

PRECAUTIONS

  • General: Nil
  • Laboratory Tests: No tests in addition to routine ICU tests are required.
  • Drug/Laboratory Test Interactions: None known.

IMPORTANT DRUG INTERACTIONS FOR THE ICU

  • None of note

ADVERSE REACTIONS:

  • Body as a Whole: Hypersensitivity reactions (e.g. fever, bronchospasm, anaphylactic shock, rash, eosinophilia)
  • Central nervous system: Malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, depression and hallucinations.
  • Cardiovascular system: Tachycardia, bradycardia, premature ventricular beats, A-V block and asystole.
  • Gastrointestinal system: Constipation, diarrhoea, nausea/ vomiting, abdominal discomfort/ pain, hepatitis, pancreatitis. Musculoskeletal system: Rare reports of arthralgias and myalgia.
  • Haematological system: Agranulocytosis or pancytopenia, sometimes with marrow hypoplasia or aplasia, have been reported.
  • Dermatological system: Rash including rare cases of mild erythema multiforme. Rare cases of vasculitis have been reported.

Critical Care Drug Manual

Print Friendly